Eisai Inc.

This phase 3 trial tested whether combining lenvatinib with either everolimus or pembrolizumab works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 1,000 participants were randomly assigned to one of three treatment groups. The study me…

This study tests whether the drug lecanemab can slow down memory loss and brain changes in people who have early signs of Alzheimer's but no symptoms yet. About 1,400 volunteers aged 55-80 with elevated brain amyloid will receive either lecanemab or a placebo for up to 4 years. T…

This study tests whether adding an experimental drug called E2814 to the approved Alzheimer's drug lecanemab can better slow the disease in people with early Alzheimer's. The trial includes 105 participants with mild cognitive impairment or mild dementia due to Alzheimer's. Resea…

This program allows people who completed certain earlier studies of perampanel to keep receiving the drug until it becomes commercially available in their country. It is for those with primary generalized tonic-clonic seizures, partial onset seizures, or Lennox-Gastaut syndrome. …

This study tests a drug called lecanemab (BAN2401) in people with early Alzheimer's disease. The goal is to see if it can slow down memory and thinking problems compared to a placebo. About 1,900 participants will be followed for 18 months, with an option to continue the drug lon…

This early-phase study tests an oral drug called E7386 in about 60 adults with advanced solid tumors that have no standard treatment options. The main goals are to find a safe dose and check for side effects. Researchers will also watch for any tumor shrinkage.

This early-phase study tests a new drug (H3B-6545) combined with an existing drug (palbociclib) in 31 women with advanced or metastatic ER+ HER2- breast cancer. The main goal is to find the safest dose and understand side effects. Participants must have already received prior tre…

This study tests a new drug, E7386, combined with other anticancer drugs for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose. About 301 participants will be involved, and the study foc…

This study is testing an experimental drug called BB-1701 for people with advanced breast cancer that has spread or cannot be removed by surgery. The trial has two parts: first to find the safest and most effective dose, and then to see how well that dose works at shrinking tumor…